Original from: business wire
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as part of the updated ¡°Advanced Tools¡± table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) .
¡°The Decipher Prostate test¡¯s performance and clinical utility have been demonstrated in many dozens of peer-reviewed, published studies, including analyses of samples from multiple prospective, Phase 3 clinical trials, making it the most validated test of its kind for prostate cancer,¡± said Phil Febbo, M.D., Veracyte¡¯s chief scientific officer and chief medical officer. ¡°We believe the Decipher Prostate test¡¯s unique status in the NCCN guidelines stems from the evidence generated through our commitment to research and our numerous collaborations with leading prostate cancer researchers around the world.¡±
The Decipher Prostate test is a whole-transcriptome-derived, 22-gene signature that clinicians use to help assess the likelihood of a prostate tumor progressing to metastatic disease. Armed with this information, the clinician may recommend less-intensive or earlier, more-intensive treatment for the patient.
¡°The Decipher Prostate test is already the most widely used molecular test in prostate cancer. We believe its unique status in the updated NCCN guidelines will help make it more accessible to even more patients,¡± said Marc Stapley, Veracyte¡¯s chief executive officer. ¡°This milestone also further reinforces the power of our Veracyte Diagnostics Platform. This novel, data-driven approach enables us to continuously develop high-performing, well-validated tests like Decipher Prostate that are transforming care for patients facing cancer.¡±
